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ABSTRACT
We investigated roles of plasma homocysteine and MTHFR gene in relation to 
risks and treatment responses of depression in ACS. A sample of 969 patients with 
recent ACS were recruited and 711 followed 1 year later. In addition, of 378 baseline 
participants with depressive disorder, 255 were randomized to a 24-week double 
blind trial of escitalopram (N = 127) or placebo (N = 128). A higher homocysteine 
concentration was independently associated with prevalent depressive disorder 
at baseline irrespective of MTHFR genotype; and with both incident and persistent 
depressive disorder at follow-up only in the presence of TT genotype. MTHFR genotype 
was not itself associated with depressive disorder after ACS. No associations were 
found with 24-week antidepressant treatment responses. Plasma homocysteine could 
be a biomarker for depressive disorder particularly in the acute phase of ACS. Focused 
interventions for those with higher homocysteine level and MTHFR TT genotype might 
reduce the risk of later depressive disorder.
INTRODUCTION
Depression is commonly comorbid with acute 
coronary syndrome (ACS) [1, 2], with multiple 
biomarkers suggested as potential explanations [3-5]. 
Homocysteine is a potential candidate, since it has been 
associated with both disorders [4]. Homocysteine can 
cause atherothrombosis by various insults on vascular 
system, and therefore increase the risk for ACS [6], as 
well as directly inhibiting monoamine neurotransmitter 
metabolism and thus linked with depression [7, 8]. 
Whether homocysteine is a common biomarker for ACS 
and depression has not yet been investigated.
Homocysteine level are influenced complex 
systems including nutritional deficiencies or supplement 
of vitamins, and medical conditions such as chronic 
kidney disease, diabetes, and malignancies [9]. 
Homocysteine levels are also strongly influenced by 
genetic factors particularly for methylenetetrahydrofolate 
reductase (MTHFR), which catalyzes the 
reduction of 5,10-methylenetetrahydrofolate to 
5-methyltetrahydrofolate. A 677C->T variant of MTHFR 
gene is responsible for thermolabile MTHFR with reduced 
enzymatic activity [10], and therefore and T allele is 
associated with higher homocysteine level [11, 12]. 
Relevant to these findings, the T allele of MTHFR gene 
has been reported to be associated with the ACS [13] and 
depression susceptibility [14]. However, it has not been 
investigated as a risk factor for depression occurring in 
ACS. 
With respect to treatment response, homocysteine 
and MTHFR C677T polymorphism have additionally been 
investigated as predictors of antidepressant response in 
patients with major depressive disorder [15, 16], but not 
to date in ACS. 
Using the data from observational prospective 
study in Koreans patients with ACS, this study aimed to 
investigate the roles of plasma homocysteine levels and 
MTHFR C677T polymorphism in relation to risks and 
treatment responses of depression in ACS. 
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RESULTS
Recruitment
The recruitment process is described in 
Supplemental Figure S1. Of the total baseline sample (n = 
1152) from larger study named the Korean DEPression in 
ACS (K-DEPACS), 969 (84.1%) agreed to provide blood 
samples. There were no significant differences between 
those who agreed or not to provide blood samples with 
respect to any baseline characteristic (all p-values > 0.15). 
Of these 969 participants, depressive disorder (major or 
minor) at baseline was present in 378 (39.0%; major and 
minor depressive disorder as 177 (18.3%) and 201(20.7%), 
respectively). Demographic and clinical characteristics 
are compared by depressive disorder at baseline in 
Supplemental Table S1. Prevalent depressive disorder 
was significantly associated with female gender, lower 
educational level, living alone, rented housing, current 
unemployment, higher Hamilton Depression Rating Scale 
(HAMD) score, presence of hypertension and diabetes, 
and current smoking. Of the baseline participants, 255 
participated in the Escitalopram for DEPression in ACS 
(EsDEPACS) trial (127 randomised to escitalopram and 
128 to placebo), 49 (19%) of whom exited from the study 
after baseline, so the remaining 206 (104 on escitalopram 
and 102 on placebo) formed the sample for the 24 week 
treatment response analysis. Of all 969 participants at 
baseline, 711 (73.4%) were successfully followed. The 
258 lost to follow-up had significantly older age and 
higher Killip class (p-values < 0.05) than those followed. 
At one year after ACS, incident depressive disorder 
was defined in 53 (12%) of the 426 participants without 
baseline depressive disorder; and persistent depressive 
disorder in 130 (46%) of the 285 participants with baseline 
depressive disorder. 
Homocysteine concentration and MTHFR 
polymorphism by depression and remission status
Plasma homocysteine concentrations and MTHTR 
genotype are compared by depressive disorder status in 
Table 1. Prevalent depressive disorder was significantly 
associated with higher homocysteine concentration, 
while incident and persistent depressive disorder were 
not. In the 24 week drug trial, the overall remission 
rate was significantly higher in the escitalopram group 
(51.9%) compared to the placebo group (34.3%) (χ2 = 
6.507, p-value = 0.011), as previously reported; however, 
homocysteine concentrations did not significantly differ by 
remission status in the total group or in the escitalopram 
or placebo group (1st row of Supplemental Table S2). 
For MTHTR genotype, no deviation from the Hardy-
Weinberg equilibrium was observed (p-values = 0.673), 
and no significant associations were found for MTHTR 
genotype with any depressive disorder or remission 
outcome (all p-values > 0.7). Logistic regression analysis 
for the associations of homocysteine concentrations and 
MTHFR genotype with depression and remission status 
after adjustment for covariates showed similar results 
(Table 2 and Supplemental Table S3).
Interactive effects of homocysteine concentration 
and MTHFR genotype on depressive status
Homocysteine levels were significantly associated 
with MTHFR genotype with mean (SD) levels 10.0 
(3.5), 11.1 (4.1), and 12.3 (6.0) μmol/l for the C/C, 
C/T T/T genotypes respectively (F = 16.8, p-value < 
0.001). Homocysteine concentrations are compared by 
depressive disorder status in each genotype in Figure 1. 
Higher homocysteine concentrations were significantly 
associated with prevalent depressive disorder in the 
Table 1: Plasma homocysteine concentrations and methylenetetrahydrofolate reductase (MTHFR) genotype by 
depressive disorder status at 2 weeks and at 1 year after acute coronary syndrome (ACS) 
Prevalent depressive disorder 
at 2 weeks after ACS
Incident depressive disorder at 
1 year after ACS
Persistent depressive disorder 
at 1 year after ACS
Absent
(N = 591)
Present
(N = 378) p-value
Absent
(N = 373)
Present
(N = 53) p-value
Absent
(N = 155)
Present
(N = 130) p-value
Homocysteine, 
mean (SD) μmol/l 10.2 (3.7) 12.0 (5.1) <0.001 10.0 (3.7) 10.7 (4.3) 0.269 11.7 (4.8) 12.6 (5.9) 0.157
MTHFR genotype, 
N(%)
C/C 214 (36.2) 128 (33.9) 0.749 136 (36.5) 18 (34.0) 0.740 51 (32.9) 41 (31.5) 0.882
C/T 277 (46.9) 185 (48.9) 177 (47.5) 28 (52.8) 73 (47.1) 65 (50.0)
T/T 100 (16.9) 65 (17.2) 60 (16.1) 7 (13.2) 31 (20.0) 24 (18.5)
p-value using t-tests or χ2 tests.
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Table 2: Multivariate analyses examining the interactive effects of homocysteine concentration and 
methylenetetrahydorfolate reductase (MTHFR) genotype on depression status
Homocysteine concentration MTHFR genotype Homocysteine concentration X MTHFR genotype
Wald OR (95% CI) Wald OR (95% CI) Wald OR (95% CI)
Prevalent depressive disordera 30.63 1.11 (1.07-1.15)*** 0.14 0.96 (0.79-1.18) 1.19 1.03 (0.98-1.08)
Incident depressive disordera 0.51 1.03 (0.95-1.11) 0.05 0.95 (0.62-1.47) 3.65 1.10 (1.00-1.20)*
Persistent depressive disorderb 1.13 1.04 (0.99-1.09) 0.17 0.93 (0.65-1.32) 3.90 1.12 (1.02-1.23)*
a adjusted for gender, education, living alone, housing, current employment, hypertension, diabetes, and current smoking
b adjujsted for the same model as in prevalent depressive disorder plus treatment status (escitalopram, placebo, and medical 
treatment only)
*p-value < 0.05, **p-value < 0.01, ***p-value < 0.001
Figure 1: Plasma homocysteine levels by depressive disorder status and methylenetetrahydrofolate reductase 
(MTHFR) genotype. Numeric data are plasma homocysteine level (μmol/l). P-values between depressive disorder status were drawn by 
logistic regression tests after adjustment for gender, education, living alone, housing, current employment, hypertension, diabetes, current 
smoking (prevalent and incident depressive disorder), plus treatment status (persistent depressive disorder). Interaction terms between 
homocysteine level and MTHFR genotype on depressive status were drawn in the same adjusted model.
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presence of C/T and T/T genotypes, and with incident and 
persistent depressive disorder only in the presence of T/T 
genotype. Homocysteine concentrations are compared by 
remission status in each genotype in the 2nd ~ 4th rows of 
Supplemental Table S2, but no significant associations 
were found. Interaction terms between genotype and 
raised homocysteine in logistic regression models after 
adjustment for covariates are summarized in 5th ~ 6th 
columns of Table 2. Significant interactions were found 
for incident and persistent depressive disorder, but not for 
prevalent depressive disorder at baseline or for any marker 
of remission status.
Associations with clinical hyperhomocysteinemia
The prevalence of hyperhomocysteinemia at baseline 
was 16.1% (156 of 969 participants), and associations 
with depressive status are displayed in Figure 2. Overall, 
the findings were similar to those of continuously 
distributed homocysteine concentrations, but the strength 
of the associations was stronger in this categorical 
approach. In the total sample, hyperhomocysteinemia 
was significantly associated with prevalent (sensitivity 
64%, specificity 63%) and incident depressive disorder, 
but not with persistent depressive disorder. When 
stratified by MTHFR genotype, hyperhomocysteinemia 
was significantly associated with prevalent depressive 
disorder in the presence of C/T and T/T genotypes, and 
with incident and persistent depressive disorder in the 
presence of T/T genotype (positive predictive value 
and negative predictive values for incident depressive 
disorder was 39 and 96%, respectively; and for persistent 
depressive disorder was 78% and 73%, respectively). 
Significant interactive effects of hyperhomocysteinemia 
and genotype were found for incident (p-value = 0.030) 
Figure 2: Depressive status by hyperhomocysteinemia and methylenetetrahydrofolate reductase (MTHFR) genotype. 
Numeric data are percentages. P-values between absent and present hyperhomocysteinemia were drawn by logistic regression tests after 
adjustment for gender, education, living alone, housing, current employment, hypertension, diabetes, current smoking (prevalent and 
incident depressive disorder), plus treatment status (persistent depressive disorder). Interaction terms between hyperhomocysteinemia and 
MTHFR genotype on depressive status were drawn in the same adjusted model.
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and persistent depressive disorder (p-value = 0.027), but 
not for prevalent depressive disorder (p-value = 0.243) 
with the same logistic regression model after adjustment. 
There were no significant individual or interactive effects 
of hyperhomocysteinemia and genotype on remission 
status in the 24 week trial (data not shown).
Sensitivity analyses
Analyses were repeated after excluding participants 
reporting a history of previous depression (N = 14), and 
no substantial differences were found in any models (data 
not shown).
DISCUSSION
Principal findings were independent associations 
between higher plasma homocysteine levels and 
depressive disorder after ACS, and differences in the 
pattern of this association by MTHFR genotype and 
time elapsed after ACS. Specifically, the cross-sectional 
association was significant regardless of MTHFR genotype 
shortly after ACS, but prospective associations were only 
significant in the presence of T allele for incidence and 
persistence of depressive disorder one year later. MTHFR 
C677T polymorphism was not itself associated with 
depressive disorder after ACS, and neither homocysteine 
levels nor MTHFR genotype were associated with 24 
week antidepressant treatment responses in the nested trial 
of escitalopram. 
Higher homocysteine levels and clinical 
hyperhomocysteinemia (above 15.0μmol/l) were 
significantly associated with prevalent depressive disorder 
shortly after ACS. Our findings are comparable to previous 
cross-sectional reports from unselected depressive patients 
[7, 17]. In addition, these results were irrespective of 
MTHFR genotype, and were not changed after excluding 
participants with a history of previous depression. 
Plausible explanations for this association were as follows. 
Homocysteine was found to be associated with dopamine 
metabolisim, serotonin deficiencies and oxidative stress 
which could be basis for depression occurrence [18, 19]. 
ACS related hyperhomocysteinemia [4] may predispose 
ACS patients to biologically vulnerable state for 
depressive disorders via theses various mechanisms and 
future research on the exact mechanisms is needed.
A primary role of the MTHFR genotype in the 
pathogenesis of depression related to ACS was not 
supported in the present study. However, it is noteworthy 
that MTHFR genotype significantly modified the 
associations of higher homocysteine levels with incident 
and persistent depressive disorder occurring in the chronic 
phase of ACS, although did not modify that with baseline 
depressive disorder. Plasma homocysteine levels were 
significantly higher in participants with higher numbers of 
T alleles, consistent with previous findings [6, 11, 12, 14]. 
T allele may confer a propensity to hyperhomocysteinemia 
which is sustained after the acute phase and acts on risk of 
depressive disorder over a longer period into the chronic 
phase of ACS, where general health and functional status 
become stronger determinants of mood state. 
Our data on the diagnostic value of clinical 
hyperhomocysteinemia with MTHFR genotyping 
at baseline suggested meaningful clinical utility for 
depressive disorders. Negative predictive value of clinical 
hyperhomocysteinemia with T/T allele for incident 
depressive disorder at 1 year after ACS was excellent 
(96.3%) and positive and negative predictive value of 
those for persistent depressive disorder was modest (77.8 
and 73.0%). Our results suggested that ACS patients 
with no hyperhomocysteinemia and C/C allele at acute 
phase were less likely to have depressive disorder newly 
at 1 year after ACS and depressive ACS patients with 
hyperhomocysteinemia and T/T allele at acute phase were 
more likely to have their depressive disorder at 1 year 
after ACS. Considering high prevalence of depressive 
disorder in ACS and usual measurement for homocysteine 
in cardiologic unit in practice due to importance of 
hyperhomocysteinemia as independent risk of ACS [20], 
plasma homocysteine assays with MTHFR genotyping 
could be utilized in the acute phase of ACS as screening 
to identify at-risk groups for depressive disorder at 1 year.
Notably, there were no significant associations of 
homocysteine levels or MTHFR genotype with 24-week 
escitalopram treatment responses evaluated in this study. 
Despite the interest in homocysteine and depression, 
modification of treatment response has received 
surprisingly little investigation. However, no association 
was found between homocysteine levels and time to 
clinical improvement with fluoxetine [15], or between 
C677T polymorphism and fluoxetine treatment response 
[16]. 
Our study has several strengths as the first 
evaluation of these questions. We were able to carry out a 
comprehensive evaluation of homocysteine and MTHFR 
genotype on the occurrence of depressive disorder in a 
large number of ACS patients with a prospective design. 
Additionally, a nested randomized placebo-controlled 
trial of the prospective study allowed investigation of 
influences on treatment response. Participants were 
recruited at baseline consecutively from all eligible 
patients with a recent ACS and were followed at 1 year 
thereafter, which reduced the risk of error arising from 
heterogeneous examination times and therefore increased 
the sample homogeneity. Depressive disorder was 
ascertained using a structured diagnostic interview, and all 
measurement methods for psychiatric and cardiovascular 
characteristics were well validated. Furthermore, a 
range of covariates were considered in the analyses. An 
important limitation is that homocysteine levels were only 
assayed at baseline and not at follow-up, since depression 
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has been associated more strongly with changes in 
homocysteine levels over time [8]. Additionally, other 
psychiatric disorders such as post traumatic disorder was 
not investigated, which made it inconclusive whether 
homocysteine was a general marker of psychiatric risk 
given or whether homocysteine was specific to depression. 
There are also potential limitations arising from attrition 
in the recruitment process, and blood analysis was only 
possible in 84% of the baseline sample, although no 
differences were found in baseline demographic and 
clinical characteristics between those with and without 
this information. The 1-year follow-up was completed 
in 73% of whole baseline participants. The attrition was 
only associated with older age and poorer cardiac status, 
and was not associated with depressive status. It therefore 
appears that ACS patients with more severe baseline 
pathology were more likely to be lost to follow-up, which 
might obscure the associations of interest.
Our results support a role of homocysteine in the 
pathogenesis of depressive disorder comorbid with ACS 
independently at acute phase and interactively with 
MTHFR genotype at chronic phase, and have several 
potential implications. Plasma homocysteine assays, 
particularly for clinical hyperhomocysteinemia, might 
thus have modest clinical utility of screening to identify 
at-risk groups for depressive disorder in the acute phase 
of ACS. Our findings may also aid to identify suitable 
therapeutic interventions. That is, depression comorbid 
with ACS also leads to very high disease burden, and is 
difficult to treat [21, 22], and assaying homocysteine and 
MTHFR genotype might allow more focused interventions 
for the prevention or management of depressive disorder 
in the late phase of ACS in more susceptible sub-groups. 
Trials of long term vitamin supplementation on depressive 
disorder have been controversial to date [23-25], but 
based on our findings, supplement effects might be more 
prominent in those with MTHFR TT genotype, at least in 
ACS patients. Relationships with the dose, duration and, 
particularly, constituents of vitamin supplements should 
therefore be investigated.
MATERIALS AND METHODS
Study outline and participants
Data were drawn for analysis from larger study 
named the Korean DEPression in ACS (K-DEPACS) 
study, which also contained a nested randomized 
controlled trial, the Escitalopram for DEPression in ACS 
(EsDEPACS) study. The overall design has been described 
in detail [26], and the recruitment process is summarized 
in Supplemental Figure S1. The K-DEPACS study was 
carried out from 2006 to investigate the epidemiology 
of depression in ACS using a observational prospective 
design. Participants were consecutively recruited from 
patients recently hospitalized with ACS (N = 4809) at 
the Department of Cardiology of Chonnam National 
University Hospital, Gwangju, South Korea. Patients 
were treated based on international guidelines for the 
management of ACS [27] by the study cardiologists. 
Those who met eligibility criteria and agreed to participate 
(N = 1152) were assessed for a depressive disorder 
diagnosis by the study psychiatrists using the Mini-
International Neuropsychiatric Interview (MINI) [28] 
as inpatients within 2 weeks post-ACS, and thereafter 
as outpatients every 4 weeks up to 12 weeks. Of these, 
969 agreed to blood assays and comprised the baseline 
sample. Of 378 patients with depressive disorder in this 
sample, 255 also agreed to participate in a 24-week, 
double-blind, nested randomized placebo-controlled 
trial of escitalopram efficacy and safety: the EsDEPACS 
study (ClinicalTrial.gov registry number: NCT00419471). 
The first patient was enrolled in May 2007 and the last 
patient completed the follow-up evaluation in March 
2013. Examinations were scheduled at baseline, and 
weeks 4, 8, 12, 16, 20, and 24 thereafter. The details and 
main results of this trial have been published, in which 
escitalopram was found to be superior to placebo in 
reducing depressive symptoms [29]. The remaining 123 
patients who declined participation in the trial received 
conventional medical treatment for ACS only. Detailed 
eligibility of the K-DEPACS and EsDEPACS studies were 
described in Supplementary Materials. All participants in 
the K-DEPACS and EsDEPACS studies were approached 
for a re-examination of depressive status at 1 year after 
the baseline evaluation. Written informed consent was 
collected for the K-DEPACS and EsDEPACS studies, 
both of which were approved by the Chonnam National 
University Hospital Institutional Review Board. 
Evaluations for depressive status
Diagnoses of depressive disorder were determined 
using the MINI, a structured diagnostic psychiatric 
interview for DSM-IV defining major or minor depressive 
disorder categories as outputs [27]. Due to the distinctive 
study design at baseline, symptom- duration criteria was 
within rather than at least 2 weeks. Depressive disorder 
was defined as the combined category, since there were 
insufficient numbers with major depressive disorder to 
analyze separately. Based on the evaluation at two phases 
after ACS, depressive disorder was ascertained as baseline 
prevalent, and follow-up incident (cases at follow-up 
within the sample who did not have depressive disorder 
at baseline) or persistent (cases at follow-up within the 
sample who did have depressive disorder at baseline). 
In the 24-week EsDEPACS trial, remission status was 
evaluated at each follow-up point, and defined on the basis 
of a HAMD score ≤7. 
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Plasma homocysteine and MTHFR C677T 
polymorphism
Blood samples were collected in a fasting state and 
were carried out in the mornings where possible. They 
were drawn into EDTA tubes, and centrifuged, separated 
into plasma aliquots, and stored at -80 oC within 2 hours 
of collection. Total plasma homocysteine concentration 
was measured using commercially available (AxSYM 
Homocysteine Reagent Pack, Abbott Laboratories, USA) 
high-performance liquid chromatography. MTHFR 
C677T genotype was determined by a polymerase chain 
reaction (PCR) and HinFI restriction enzyme digestion 
as described previously8 with miner modification. HinfI 
digestion (1.5U/25μL reaction mixture) was performed 
directly in the PCR tube at 37 oC for 4 hours before 
analysis of restriction fragments by polyacrylamide gel 
electrophoresis. 
Demographic and clinical covariates
Characteristics potentially acting as confounding 
or mediating factors for associations between depressive 
disorder and ACS were evaluated at baseline. Data on age, 
gender, duration of education, living status (living alone 
or not), accommodation tenure (owned or rented), current 
occupation (employed or not), and previous and family 
histories of depression were obtained. The following 
cardiovascular risk factors were ascertained: previous 
and family histories of ACS, diagnosed hypertension 
and diabetes mellitus, hypercholesterolemia by fasting 
serum total cholesterol level (>200mg/dL), obesity by 
measured body mass index (BMI), and reported current 
smoking status. For current cardiac status, severity of 
ACS was estimated by the Killip classification [30], 
left ventricular ejection fraction (LVEF) was estimated 
using echocardiography, and serum cardiac biomarkers 
on troponin I and creatine kinase-MB (CK-MB) were 
measured. Other factors can affect the homocysteine 
concentrations were considered: serum creatinine level 
and vitamin supplementation.
Statistical analyses
Demographic and clinical characteristics were 
compared between patients with and without prevalent 
depressive disorder at baseline using t-tests or χ2 tests, as 
appropriate. Characteristics significantly associated with 
depressive disorder (P < 0.05) were used as covariates 
in further regression models. Plasma homocysteine was 
first considered as a continuous value. Homocysteine 
concentration and MTHFR C677T polymorphism were 
compared between those with and without prevalent/
incident/persistent depressive disorder using t-tests 
and χ2 tests, respectively. In the 24-week EsDEPACS 
trial, homocysteine concentration and MTHFR C677T 
polymorphism were compared between those who did 
or did not achieve remission using t-tests and χ2 tests, 
respectively. Odds ratios (ORs) for depression and 
remission status were estimated using logistic regression 
models, adjusting for relevant covariates. To investigate 
the potential interactive effects of homocysteine 
concentration and MTHFR C677T polymorphism 
on depressive status and remission status, following 
analyses were carried out: i) homocysteine concentration 
was compared between genotypes using ANOVA, ii) 
associations between homocysteine concentration and 
depressive status were evaluated in each genotype; iii) 
two way interactions between homocysteine concentration 
and genotype were tested using multivariate logistic 
regression models. Additional analyses were carried out 
to investigate associations with a clinically significant 
category of hyperhomocysteinemia defined as a plasma 
level above 15.0 μmol/l [31] with the same analytic 
methods above. Additionally, diagnostic statistics namely, 
sensitivity, specificity, positive predictive value and 
negative predictive values were calculated for depressive 
disorder status. 
Finally, sensitivity analyses were carried out with 
the same analytic methods after excluding participants 
with a previous history of depression. Statistical analyses 
were carried out using SPSS 18.0 software.
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